Bailey CJ, Day C. Treatment of type 2 diabetes: future approaches. Brit Med Bull 2018;126:123-37. https://doi.org/10.1093/brimed/ldy013

Bailey CJ. The current drug treatment landscape for diabetes and perspectives for the future. Clin Pharmacol Ther 2015;98:170-84. https://doi.org/10.1002/cpt.144

Bliss Michael. The discovery of insulin. Toronto: McClelland & Stewart; 1982.

Tattersall R. Pancreatic organotherapy for diabetes, 1889-1921. Med Hist 1995;39:288–316. https://doi.org/10.1017/s002572730060087

Alberti KGMM, Bailey CJ. The discovery of insulin. Brit J Diabetes 2022; 22(Supp1):S3-S5. https://doi.org/10.15277/bjd.2022.352

Diema P, Ducluzeaub PH, Scheen A. The discovery of insulin. Diabetes Epidemiology Management 2022;5:100049. https://doi.org/10.1016/j.deman.2021.100049 Accessed 18 October 2022.

Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med 1922;7:251-66. PMID:17582843

Zuelzer G. Ueber Versuche einer specifischen Fermenttherapie des Diabetes. Zeitschrift für die experimentelle Pathologie und Therapie 1908;5:307–18.

Paulescu NC. Recherches sur le rôle du pancréas dans l'assimilation nutritive. Arch Int Physiol 1921;17:85–109.

Himsworth HP. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936;227:127-30. https://doi.org/10.1093/ije/dyt203

Lister J, Nash J, Ledingham U. Constitution and insulin sensitivity in diabetes mellitus. Br Med J 1951;1[4703]:376-9. https://doi.org/10.1136/bmj.l.4703.376

Hadden DR. Goat’s rue—French lilac – Italian fitch – Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edin 2005;35:258–60. PMID:16402501

Bailey CJ, Day C. Metformin: its botanical background. Pract Diabetes Int 2004;21:115–17. https://doi.org/10.1002/pdi.606

Werner EA, Bell J. The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyandiamide, and methylammonium and dimethylammonium chlorides respectively. J Chem Soc Trans 1922;121: 1790–1794. https://doi.org/10.1039/CT9222101790

Hesse G, Taubmann G. Die Wirkung des Biguanids und seiner Derivate auf den Zuckerstoffwechsel. Arch Exp Path Pharmacol 1929;142:290–308 [article in German].

Slotta KH, Tschesche R. Uber Biguanide. Die blutzuckersenkende Wirkung der Biguanides. Ber Dtsch Chem Ges 1929;62:1398–405 [article in German]. https://doi.org/10.1002/aber.10=9290620604

Garcia EY. Flumamine, a new synthetic analgesic and anti-flu drug. J Philippine Med Assoc 1950; 26:287–93. PMID: 14779282

Pasik C. Jean Sterne: a passion for research. In: Pasik C (ed) Glucophage: serving diabetology for 40 years. Lyon, Groupe Lipha, 1997; pp 29–31.

Sterne J. Du nouveau dans les antidiabétiques. La NN dimethylamine guanyl guanidine (N.N.D.G.) Maroc Med 1957; 36: 1295–1296 [article in French]

Bailey CJ. Metformin: historical overview. Diabetologia 2017;60:1566-76. https://doi.org/10.1007/s00125-017-4318-z

Bailey CJ, Turner RC. Drug therapy: metformin. N Engl J Med 1996;334: 574–79. https://doi.org/10.1056/NEJM199602293340906

Janbon M, Chaptal J, Vedel A, Schaap J. Accidents hypoglycémiques graves par un sulfamidothiodiazol (le VK 57 ou 2254 RP). Montpellier Med 1942; 441:21–22.

Loubatières A. The mechanism of action of the hypoglycemic sulphonylureas: a concept based on investigations in animals and man. Diabetes 1957;6:408–17. https://doi.org/10.2337/diab.6.5.408

Tattersall R. Discovery of the sulphonylureas. Diabetes on the Net 2008;7:74. https://diabetesonthenet.com/diabetes-digest/discovery-of-the-sulphonylureas/ Accessed 21 October 2022.

Kleinsorge H. Carbutamide -the first oral antidiabetic. A retrospect. Exp Clin Endocrinol Diabetes 1998;106:149-51. https://doi.org/10.1055/s-0029-12119687

Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321:1231-45. https://doi.org/10.1056/NEJM198911023211805

Lebovitz HE, Melander A. Sulfonylureas: basic aspects and clinical uses. In International Textbook of Diabetes Mellitus, 3rd edition, DeFronzo RA, Ferrannini E, Keen H, Zimmet P (eds). Wiley, Cichester, 2004, 801-31. https://onlinelibrary.wiley.com/doi/abs/10.1002/0470862092.d0608

Boyd AE. Sulfonylurea receptors, ion channels, and fruit flies. Diabetes 1988;37:847-50. https://doi.org/10.2337/diab.37.7.847

Geisen K, Hübner M, Hitzel V, et al. Acylaminoalkyl substituted benzoic and phenylalkane acids with hypoglycaemic properties. Arzneimittelforschung 1978;28:1081-3.PMID:582693

Garrino G, Schmeer W, Nenquin M, Meissner HP, Henquin JC. Mechanism of the stimulation of insulin release in vitro by HB 699, a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide. Diabetologia 1985;28:697–703. https://doi.org/10.1007/BF00291979

Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358:1709-16. https://doi.org/10.1016/S0140-6736(01)06715-0

Puls W, Keup U. Inhibition of sucrase by tris in rat and man, demonstrated by oral loading tests with sucrose. Metabolism 1975;24:93-8. https://doi.org/10.1016/0026-0495(75)90010-4

Lebovitz HE. Oral antidiabetic agents. the emergence of alpha-glucosidase inhibitors. Drugs 1992;44(Suppl3):21-8. https://doi.org/10.2165/00003495-199200443-00004

Sohda T, Mizuno K, Imamiya E, et al. Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. Chem Pharm Bull (Tokyo) 1982;30:3580- 600. https://doi.org/10.1248/cpb.30.3580

Devchand PR, Liu T, Altman RB, FitzGerald GA, Schadt EE. The pioglitazone trek via human PPAR gamma: from discovery to a medicine at the FDA and beyond. Front Pharmacol 2018;01093. https://doi.org/10.3389/fphar.2018.01093 Accessed 22 October 2022

Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drugs and cardiovascular risks: A Science Advisory from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol 2010;55:1885–94. https://doi.org/10.1016/j/jacc.2020.02.014

Bailey CJ. Safety of antidiabetes medications: an update. Clin Pharmacol Ther 2015;98:185-95. https://doi.org/10.1002/cpt.125

Holst JJ. From the incretin concept and the discovery of GLP-1 to today's diabetes therapy. Front Endocrinol 2019;00260. https://doi.org/10.3389/fendo.2019.00260 Accessed 22 October 2022

Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705. https://doi.org/10.1016/S0140-6736(06)69705-5

Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126–31. https://doi.org/10.2337/diab.44.9.1126

Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-05. https://doi.org/10.1016/S0021-9258(18)42531-8

Interview with John Eng. Dr John Eng’s research found that the saliva of the Gila Monster contains a hormone that treats diabetes better than any other medicine. Diabetes in Control, 2007. https://www.diabetesincontrol.com/dr-john-engs-research-found-that-the-saliva-of-the-gila-monster-contains-a-hormone-that-treats-diabetes-better-than-any-other-medicine/ Accessed 23 October 2022

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab 2021;46: 101102. https://doi.org/10.1016/j.molmet.2020.101102

De Block C, Bailey C, Wysham C, Hemmingway A, Allen SE, Peleshok J. Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes Obes Metab 2022; https://doi.org/10.1111/dom.14831. Online ahead of print.

Foley JE, Ahrén B. The Vildagliptin Experience — 25 years since the initiation of the Novartis glucagon-like peptide-1 based therapy programme and 10 years since the first vildagliptin registration. Eur Endocrinol 2017;13:56–61. https://doi.org/10.17925/EE.2017.13.02.56

Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1- adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774–89. https://doi.org/10.1021/jm0300911

Thornberry NA, Weber AE. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 2007;7:557-68. https://doi.org/10.2174/156802607780091028

Jörgens V. The roots of SGLT inhibition: Laurent-Guillaume de Koninck, Jean Servais Stas and Freiherr Josef von Mering. Acta Diabetol 2019;56:29-31. https://doi.org/10.1007/s00592-018-1206-z

Valdes-Socin H, Scheen AJ, Jouret F, Grosch S, Delanaye P. From the discovery of phlorizin (a Belgian story) to SGLT2 inhibitors. Rev Med Liege 2022;77: 175-80. [article in French]. PMID:35258866

Chasis H, Jolliffe N, Smith HW. The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest 1933;12:1083–90.

Crane RK. Intestinal absorption of sugars. Physiol Revs 1960;40:789–825. https://doi.org/10.1152/physrev.1960.40.4.789

Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510–15. https://doi.org/10.1172/JCI112981

Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145–9. https://doi.org/10.1021/jm701272q

Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013;1:140–51. https://doi.org/10.1016/S2213-8587(13)70050-0

McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta- analysis. JAMA Cardiol 2021;6:148-58. https://doi.org/10.1001/jamacardio.2020.4511

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022;65:1925–66. https://doi.org/10.1007/s00125-022-05787-2

Day C, Bailey CJ. The hypocaloric diet in type 2 diabetes - déjà vu. Br J Diab Vasc Dis 2012;12:48-52. https://doi.org/10.1177/1474651412437503